Upadacitinib

Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial…

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis. Upadacitinib is a Janus kinase (JAK) inhibitor that works by blocking the action of enzymes called Janus kinases.

These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control. Common side effects include upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever. Upadacitinib was approved for medical use in both the United States and the European Union in 2019.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370557393 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

21 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.